Kinney Horn sold $2.3M of IMNM
CHIEF BUSINESS OFFICER at Immunome Inc.. 90,616 shares at an average of $25.09, traded Aug 4, 2026, filed Aug 6, 2026.
Score components
- +15RoleOfficer
- +25Trade size$2.3M at market
- +20Share of holdings soldSold 100% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001831215-26-000005, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 4, 2026 | MOption exercise Common Stock10b5-1 | +50,366 | $12.92 | $651k | 50,366 | Aug 6, 2026 |
| Aug 4, 2026 | MOption exercise Common Stock10b5-1 | +40,250 | $10.60 | $427k | 90,616 | Aug 6, 2026 |
| Aug 4, 2026 | SOpen-market sale Common Stock10b5-1 | -90,616 | $25.09 | $2.3M | 0 | Aug 6, 2026 |
| Aug 4, 2026 | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -50,366 | $0.00 | $0 | 78,542 | Aug 6, 2026 |
| Aug 4, 2026 | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -40,250 | $0.00 | $0 | 120,750 | Aug 6, 2026 |
Related signals
Other insiders at Immunome Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | Immunome Inc. | Jack Higgins Chief Scientific Officer | $334k 13,200 shares | -17% | |
| 48Moderate | Immunome Inc. | Isaac Barchas director | $2.2M 83,464 shares | -115% | |
| 37Weak | Immunome Inc. | Isaac Barchas director | $940k 36,088 shares | -33% | |
| 20Weak | Immunome Inc. | Kinney Horn CHIEF BUSINESS OFFICER | $27k 1,092 shares | -100% | |
| 45Moderate | Immunome Inc. | Isaac Barchas director | $2.4M 100,000 shares | -48% | |
| 40Moderate | Immunome Inc. | Robert Lechleider Chief Medical Officer | $1.2M 55,000 shares | -78% | |
| 45Moderate | Immunome Inc. | Isaac Barchas director | $4.4M 201,050 shares | -49% | |
| 40Moderate | Immunome Inc. | Robert Lechleider Chief Medical Officer | $1.1M 55,000 shares | -78% | |
| 47Moderate | Immunome Inc. | Max Rosett Chief Financial Officer | $1.1M 60,000 shares | -53% | |
| 46Moderate | IMNMbuy Immunome Inc. | Jean Jacques Bienaime director | $204k 10,500 shares | +32% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.